Congenital malformations

Current Opinion in Obstetrics and Gynecology

Volumn 8, Issue 6, 1996, Pages 412-416

  Gadow, Enrique C ^a   Otaño, Lucas ^a   Lippold, Santiago E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; FOLIC ACID; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DIET SUPPLEMENTATION; DOWN SYNDROME; EARLY DIAGNOSIS; GENETIC COUNSELING; HUMAN; META ANALYSIS; NEURAL TUBE DEFECT; PRENATAL SCREENING; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW;

EID: 0030477701     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199612000-00005     Document Type: Review

References (32)

1. Sever L, Lynberg MC, Edmonds LD: The impact of congenital malformations on public health. In Congenital Malformations Surveillance. Atlanta, Georgia: US Department of Health & Human Services, Center for Diseases Control, 1993, 48:547-549.
2. Congenital Malformations Worldwide. A Report from the International Clearinghouse for Birth Defects Monitoring System. Amsterdam: Elsevier Science Publishers; 1991.
3. Croen LA, Shaw GM: Young maternal age and congenital malformations: a population-based study. Am J Public Health 1995, 85:710-713. Evaluation of the prevalence of congenital anomalies among mothers younger than 20 years of age compared with 25-29-year-old mothers from the California Birth Defects Monitoring Program.
4. Roberts HE, Moore CA, Cragan JD, Fernhoff PM, Kohury MJ: Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990-1991. Pediatrics 1995, 96:880-883. A study that shows the reduction in the prevalence of NTDs from 1971 to 1990-1991, and estimates to what extent this reduction could be attributed to prenatal diagnosis.
5. Folic Acid and the Prevention of Neural Tube Defects. Report from an Expert Advisory Group. London: Department of Health; 1992.
6. Cuskelly GJ, McNulty H, Scott JM: Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet 1996, 347:657-658. This study uses assessment of changes in red-cell folate to evaluate the effectiveness of three different ways recommended to achieve an intake of 400 μg daily of folic acid.
7. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM: Risk of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995, 345:393-396. The objective was to investigate whether maternal multivitamin use reduced the risk of delivering offspring with orafacial clefts.
8. Czeizel AE: Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ 1993, 306:1645-1648.
9. Paz JE, Otaño L, Gadow EC, Castilla EC: Previous miscarriage and stillbirth as risk factors for other unfavorable outcomes in the next pregnancy. Br J Obstet Gynaecol 1992, 99:808-812.
10. Wald NJ: Guidance on Terminology. J Med Screening 1994, 1:76.
11. Marteau TM: Towards informed decisions about prenatal testing: a review. Prenat Diagn 1995, 15:1215-1226. A review on how best to inform patients about prenatal screening and their reproductive options following diagnosis of a congenital malformation. To this purpose, several approaches are described such as staff- and patient-focused interventions and training.
12. Simpson JL, Palomaki GE, Mercer B, Haddow JE, Andersen R, Sibai B, Elias S: Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum α-fetoprotein measurements. Am J Obstet Gynecol 1995, 173:1742-1748. A cohort study with obstetric outcome of 650 women with a singleton pregnancy without a NTD. Pre-term, premature rupture of the membranes, pre-term birth, and low birthweight were found to be associated with second-but not third-trimester maternal serum AFP elevations.
13. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Barsel Bowers G: Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992, 327:588-593.
14. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L: Antenatal maternal serum screening for Down's syndrome: results of a demonstration project BMJ 1992, 305:391-394
15. Brambati B, Tului L, Bonacchi I, Shrimanker K, Suzuki Y, Grudzinskas JG: Serum PAPP-A and free beta-hCG are first trimester screening markers for Down's Syndrome. Prenat Diagn 1994, 14:1043-1047.
16. Roberts LJ, Bewley S, Mackinson AM, Rodeck CH: First trimester fetal nuchal translucency: problems with screening the general population 1. Br J Obstet Gynaecol 1995, 102:381-385.
17. Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJM, Nicolaides KH: The implementation of first trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 1995, 5:20-25.
18. Bizot ML, Snijders RJM, Bersinger NA, Kuhn P, Nicolaides KH: Maternal serum pregnancy-associated placental protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994, 84:918-922.
19. Bizot ML, Snijders RJM, Butler J, Bersinger NA, Nicolaides KH: Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 1995, 102:127-132. A retrospective study indicating that screening for trisomies can be achieved by combining determination of fetal nuchal translucency thickness and maternal serum biochemistry.
20. Wald NJ, Kennard A, Hackshaw AK: First trimester serum screening for Down's Syndrome. Prenat Diagn 1995, 15:1227-1240. A review of the published literature on early screening and its efficacy, and the results from a multi-centre study on ultrasound markers for Down's syndrome at 8-14 weeks' pregnancy.
21. Bucher H, Schmidt J: Does routine ultrasound scanning improve outcoming in pregnancy? Meta-analysis of various outcome measures. BMJ 1993, 307:13-17.
22. Crane J, LeFevre M, Winborn R, Evans J, Ewigman B, Bain R, Frigoletto E, McNellis D, and the RADIUS Study Group: A randomized trial of prenatal outcome of anomalous fetuses. Am J Obstet Gynecol 1994, 171:392-399.
23. Barnhard Y, Bar-Hava I, Divon MY: Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? Am J Obstet Gynecol 1995, 173:1523-1527. A prospective study of 2730 third-trimester pregnant women to determine the frequency of chromosomal anomalies in cases of polyhydramnios. Growth-retarded fetuses with polyhydramnios warrant genetic evaluation, which was found not to be absolutely indicated in patients with polyhydramnios and a sonographically normal fetus.
24. Chitty L: Ultrasound screening for fetal abnormalities. Prenat Diagn 1995, 15:1241-1257. A review on routine ultrasound screening studies and alternative anomaly screening policies. The majority of routine anomaly scanning is done in the second trimester, but there may be a case for screening at other times in pregnancy.
25. Pandya PP, Kondylios A, Hilbert I, Snijders RJM, Nicolaides KH: Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995, 5:155-19.
26. Gillum RF: Epidemiology of congenital heart disease in the United States. Am Heart J 1994, 127:919-927.
27. Mastroiacovo P, Botto L, Zampino G: Epidemiology of congenital cardiac defects [in Italian]. In Cardiopatie Congenite e Sindromi Genetiche. Milan: McGraw Hill; 1995:13-19.
28. Lindsey DA: Echocardiography detection of congenital heart disease in the fetus: present and future. Br Heart J 1995, 74:103-106. A study reporting that improved resolution of ultrasound equipment and the addition of pulsed, continuous wave and colour flow Doppler would allow the prenatal detection of cardiac malformations.
29. Rustico MA, Benettoni A, D'Ottavio G, Maieron A, Fischer-Tamaro I, Conoscenti G, Meir Y, Montesano M, Cattaneo A, Mandruzzato G: Fetal heart screening in low-risk pregnancies. Ultrasound Obstet Gynecol 1995, 6:313-319.
30. Tegnander E, Eik-Nes SH, Johansen OJ, Linker DT: Prenatal detection of heart defects at the routine fetal examination at 18 weeks in a non-selected population. Ultrasound Obstet Gynecol 1995, 5:372-380.
31. Cooper MJ, Enderlein MA, Dyson DC, Rogé CL, Tarnoff H: Fetal echocardiography: retrospective review of clinical experience and an evaluation of indications. Obsret Gynecol 1995, 86:577-582.
32. Williams JO: The accuracy of antenatal fetal echocardiography screening in high- and low-risk patients. Am J Obstet Gynecol 1995, 172:1741-1749. A two-cohort prospective study showing poor diagnostic accuracy of the standard four-chamber and left ventricular outflow tract views in low-risk patients for the diagnosis of structural cardiac anomalies.